Références

Information sur le cancer / Types de cancer / Poumon / Traitement / Stade 4

Alberta Health Services. (2013, November). Clinical Practice Guideline LU-004 Non-Small Cell Lung Cancer Stage IV. Extrait de: http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-lu004-nsclc-stage4.pdf.

American Cancer Society. (2016, May). Lung Cancer (Non-Small Cell). Extrait de: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf.

Detterbeck FC, Decker RH, Tanoue L, Lilenbaum RC. Non-small cell lung cancer. DeVita VT Jr, Lawrence TS, Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Édition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 41: 495-535.

Drugs and Health Products, Health Canada. (2017, August 27). Regulatory Decision Summary: Xalkori. Extrait de: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00285.

Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib (Iressa), erlotinib (Tarceva), afatinib, dacomitinib or icotinib in the treatment of non-small cell lung cancer: a clinical practice guideline. (2014, May 8). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. No.: 7-9 Version 2.

Health Canada. (2018, June 5). Regulatory Decision Summary - Zykadia. Extrait de: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00387.

Kulkarni S, Vella, E, Coakley N, Cheng S, Gregg R, Ung YC, Ellis PM. The use of systemic treatment in the maintenance of patients with non-small call lung cancer. (2015, August 14). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. No.:7-22.

Lung Cancer Disease Site Group. Altered fractionation of radical radiation therapy in the management of unresectable non-small cell lung cancer. Cancer Care Ontario. (2013, May 16). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. No.7-12 Version 2.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 4.2016). Extrait de: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Princess Margaret Cancer Centre. (2015, September). Princess Margaret Cancer Centre Clinical Practice Guidelines: Lung Cancer. Extrait de: http://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Lung/Documents/CPG_Lung_LungCancer.pdf.

Saskatchewan Cancer Agency. (2015, April 1). Provincial Non-Small Cell Lung Cancer Treatment Guidelines. (Updated Édition).

Tyson LB, Ginex PK. Non–small cell lung cancer. Houlihan NG & Tyson LB (eds.). (2012). Lung Cancer. (2nd Édition). Pittsburgh: Oncology Nursing Society. 9:99-130.

Ung Y, Yu E, Falkson C, et al. The role of high dose rate brachytherapy in the palliation of symptom in patients with non-small cell lung cancer: a clinical practice guideline. Cancer Care Ontario. (2005, October). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. No. 7-16 Version 2.

×
×